{"id":"biothrax","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BioThrax","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:48:45.589722+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:49:05.566003+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:48:52.313040+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BioThrax","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:48:53.084531+00:00"}},"_dailymed":{"setId":"e0b11800-8922-11df-b3d7-0002a5d5c51b","title":"BIOTHRAX (ANTHRAX VACCINE ADSORBED) INJECTION, SUSPENSION [EMERGENT BIODEFENSE OPERATIONS LANSING, LLC]"},"aiSummary":"BioThrax is a marketed drug developed by the Biomedical Advanced Research and Development Authority, primarily indicated for the prevention of anthrax disease. The drug holds a unique position in the market due to its specific indication and the absence of direct competitors. However, the key composition patent is set to expire in 2028, posing a significant risk to revenue sustainability.","_scrapedAt":"2026-03-28T00:21:08.491Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:49:05.566805+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT05997264","phase":"PHASE2","title":"Anthrax AV7909 Boost Evaluation Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2023-12-05","conditions":"Anthrax","enrollment":220},{"nctId":"NCT07268612","phase":"","title":"Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.","status":"NOT_YET_RECRUITING","sponsor":"Emergent BioSolutions","startDate":"2035-11","conditions":"Anthrax","enrollment":250},{"nctId":"NCT04067011","phase":"PHASE2","title":"Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2019-08-12","conditions":"Anthrax","enrollment":210},{"nctId":"NCT03352466","phase":"PHASE1","title":"NasoShield Study of Safety and Immunogenicity","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2018-01-18","conditions":"Healthy Volunteers","enrollment":145},{"nctId":"NCT04415749","phase":"PHASE1","title":"NasoShield in Healthy Adults to Study Safety and Immunogenicity","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2020-06-15","conditions":"Healthy Volunteers","enrollment":43},{"nctId":"NCT01753115","phase":"PHASE2","title":"Ciprofloxacin BioThrax Co-Administration Study","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2012-12","conditions":"Anthrax","enrollment":154},{"nctId":"NCT04660201","phase":"PHASE1","title":"Anthrax AV7909 Liquid vs Lyophilized","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-05-25","conditions":"Anthrax, Anthrax Immunisation","enrollment":41},{"nctId":"NCT00119067","phase":"PHASE4","title":"Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2002-05","conditions":"Healthy","enrollment":1564},{"nctId":"NCT01491607","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2011-11","conditions":"Anthrax","enrollment":200},{"nctId":"NCT03877926","phase":"PHASE3","title":"VELOCITY: An Anthrax Vaccine Clinical Study","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2019-03-11","conditions":"Anthrax","enrollment":3862},{"nctId":"NCT01263691","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2010-12","conditions":"Bacillus Anthracis (Anthrax) Infection","enrollment":105},{"nctId":"NCT02339155","phase":"PHASE4","title":"Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2015-02-24","conditions":"Infections, Bacterial","enrollment":573},{"nctId":"NCT01979406","phase":"PHASE1","title":"A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2013-11","conditions":"Anthrax Infection","enrollment":120},{"nctId":"NCT01770743","phase":"PHASE2","title":"A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2013-01","conditions":"Anthrax","enrollment":168},{"nctId":"NCT01653392","phase":"","title":"BioThrax® (Anthrax) Vaccine in Pregnancy Registry","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2012-07","conditions":"Pregnancy Complications, Pregnancy Outcome, Congenital Abnormalities","enrollment":98},{"nctId":"NCT01624532","phase":"PHASE2","title":"A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2021-07-14","conditions":"Anthrax","enrollment":240},{"nctId":"NCT04148118","phase":"PHASE1","title":"A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"BlueWillow Biologics","startDate":"2020-01-08","conditions":"Anthrax","enrollment":84},{"nctId":"NCT03518125","phase":"PHASE2","title":"BARDA Securing Anthrax Immunity For the Elderly","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2018-05-09","conditions":"Anthrax","enrollment":305},{"nctId":"NCT02655549","phase":"PHASE1","title":"A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Pfenex, Inc","startDate":"2015-12","conditions":"Anthrax","enrollment":54},{"nctId":"NCT00114621","phase":"PHASE1","title":"Anthrax Vaccine Clinical Trials","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2004-09-08","conditions":"Anthrax","enrollment":93},{"nctId":"NCT02239172","phase":"PHASE1","title":"PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine","status":"COMPLETED","sponsor":"Fraunhofer, Center for Molecular Biotechnology","startDate":"2014-08","conditions":"Anthrax","enrollment":30},{"nctId":"NCT01641991","phase":"PHASE4","title":"Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-07","conditions":"Bacillus Anthracis (Anthrax)","enrollment":328},{"nctId":"NCT01867957","phase":"PHASE1","title":"Efficacy and Safety of Anthrax Vaccine, GC1109","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-02","conditions":"Anthrax","enrollment":20},{"nctId":"NCT00057525","phase":"PHASE1","title":"A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults","status":"COMPLETED","sponsor":"DynPort Vaccine Company LLC, A GDIT Company","startDate":"2003-04","conditions":"Anthrax","enrollment":70},{"nctId":"NCT00133484","phase":"PHASE2","title":"UMD rPA Regimen Trial in Adults","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Bacillus Anthracis (Anthrax)","enrollment":270},{"nctId":"NCT00063843","phase":"PHASE1","title":"Anthrax-rPA: Safety, Tolerability, Immunogenicity","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-07","conditions":"Anthrax","enrollment":80},{"nctId":"NCT00170456","phase":"PHASE2","title":"Phase II Study of Range and Schedule of rPA Doses","status":"COMPLETED","sponsor":"PharmAthene UK Limited","startDate":"2005-03","conditions":"Prevention of Bacillus Anthracis (Anthrax) Infection","enrollment":415},{"nctId":"NCT00170469","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed","status":"COMPLETED","sponsor":"PharmAthene UK Limited","startDate":"2005-03","conditions":"Bacillus Anthracis (Anthrax)","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":63,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anthrax Vaccine Adsorbed (AVA)","Anthrax Vaccine Adsorbed","AVA"],"phase":"marketed","status":"active","brandName":"BioThrax","genericName":"BioThrax","companyName":"Biomedical Advanced Research and Development Authority","companyId":"biomedical-advanced-research-and-development-authority","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":2},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:49:05.566805+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}